<DOC>
	<DOCNO>NCT02737319</DOCNO>
	<brief_summary>The investigator analyze HMG-CoA reductase inhibitor , rosuvastatin , prevention contrast-medium-induced nephropathy patient undergo primary angioplasty .</brief_summary>
	<brief_title>A Randomized Trial Rosuvastatin Elective Angioplasty Prevent Contrast-induced Nephropathy ( CLEAR-CIN ) .</brief_title>
	<detailed_description>Patients stable coronary artery disease already take chronic statin undergo elective angioplasty risk contrast-medium-induced nephropathy specify risk factor age 75 year , chronic renal insufficiency , diabetes , use contrast lack effective prophylaxis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>chronic statin use positive stress test finding ( electrocardiography , nuclear imaging , stress echocardiography elective angioplasty . nonstatin therapy presentation ACS within 24 hour time randomization current use potent CYP3A4 inhibitor , include azole antifungal , protease inhibitor , macrolide antibiotic , cyclosporine renal replacement therapy , history kidney transplant , pregnant renal failure ( serum creatinine &gt; 3.0 mg/dl ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Contrast , nephropathy , angioplasty , stable coronary</keyword>
</DOC>